Zak Mir takes a technical analysis look at some of the most followed small caps on the London market. Today’s selection includes Avacta, Amigo, Audioboom, Galileo Resources, JKX, United Oil
Response to press speculation regarding a possible merger of Avast with NortonLifeLock Inc.
Zak Mir takes a technical analysis look at some of the most followed small caps on the London market. Today’s selection includes Avacta, Omega Diagnostics, Open Orphan and Xtract Resources.
Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that Avacta Life Sciences’ diagnostics
Shares of Edtech specialist Dev Clever (DEV) bounced back 3.5p to 45p, in the wake of Monday’s Half-Year Report. The financial highlight here was that revenue rose 531% at £2.4m
Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that a study has shown
We spoke with Bill Brodie Good, CEO & Technical Director of Alien Metals covering the exploration project on Donovan 2. Joe Salomon, Managing Director of Oilex, updated with the Cambay
Registration of Avacta’s AffiDX® SARS-CoV-2 Antigen Lateral Flow Test in EU
Been a good week for company updates, we interviewed Alien Metals Ltd who are delivering news on a weekly basis right now with the Phase 2 drilling commences on Hancock
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, notes speculation regarding the ongoing CE mark submission for
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that its Annual Report and
